Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.
We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C. The patient received the interferon for four months.
Nouri
K
K
University of Miami School of Medicine, Department of Dermatology and Cutaneous Surgery, Florida, USA.
Busso
M
M
Machler
B C
BC
D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D014820:Vitiligo / Q000139:chemically induced*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins